George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Exercise of Warrants

15 May 2020 07:00

RNS Number : 9759M
Motif Bio PLC
15 May 2020
 

 

Motif Bio plc

("Motif Bio" or the "Company")

 

Exercise of Warrants

 

Motif Bio plc (AIM: MTFB), which has been reclassified as an AIM Rule 15 cash shell, announces that it has received notification from a warrant holder to exercise warrants representing 7,142,857 ordinary shares of 0.01p each ("Ordinary Shares") in the Company for total consideration of £48,571.43. The exercise price of all warrants was 0.68p per warrant.

 

Application has been made for the 7,142,857 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 20 May 2020. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury.

 

Following Admission, and further to the announcement made on 5 May 2020, and for the purposes of the Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 654,991,023 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

For further information please contact:

 

 

Motif Bio plc

 

ir@motifbio.com

Jonathan Gold (President and Chief Business Officer)

 

 

 

SP Angel Corporate Finance LLP (NOMAD & BROKER)

+44 (0)20 3470 0470

David Hignell/Caroline Rowe (Corporate Finance)

 

Vadim Alexandre/Abigail Wayne (Sales & Broking)

 

 

 

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

+44 (0)20 7933 8780

Paul McManus/ Lianne Cawthorne

motifbio@walbrookpr.com

 

 

Forward-Looking Statements

When used in this Press Release, the words or phrases "intends," "anticipates," "expected to be" or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties including, but not limited to, changes in economic conditions in the Company's market area, changes in policies by regulatory agencies, fluctuations in interest rates, competition that could cause actual results to differ materially from historical earnings and those presently anticipated or projected, and other risks described in the Company's filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company advises readers that the factors listed above could affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed with respect to future periods in any current statements. The Company does not undertake, and specifically disclaims any obligation, to publicly release the result of any revision which may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOESFEFMLESSEFI
Date   Source Headline
8th Jun 20172:32 pmRNSHolding(s) in Company
5th Jun 20176:20 pmRNSPublication of Shareholder Circular
2nd Jun 20174:36 pmRNSResult of Placing
2nd Jun 20177:00 amRNSProposed Placing
23rd May 20174:40 pmRNSSecond Price Monitoring Extn
23rd May 20174:35 pmRNSPrice Monitoring Extension
18th May 20177:00 amRNSPublication of UK Annual Report and Accounts
10th May 20177:00 amRNSAppointments to Scientific Advisory Board
5th May 20177:00 amRNSDirectorate Change
2nd May 20173:10 pmRNSExercise of Warrants and Issue of Equity
2nd May 20177:00 amRNSAnnual Financial Report
28th Apr 201712:00 pmRNSChange of Adviser
24th Apr 20177:00 amRNSNotification of change in holding of shareholder
18th Apr 20177:00 amRNSPositive Data Readout for Iclaprim Phase 3 Trial
12th Apr 20173:06 pmRNSHolding(s) in Company
12th Apr 20173:01 pmRNSHolding(s) in Company
31st Mar 20174:15 pmRNSChange of Registered Office
8th Feb 20172:57 pmRNSInvestor Presentation
8th Feb 20177:00 amRNSDirector/PDMR Shareholding
7th Feb 20177:02 amRNSDirector/PDMR Shareholding
31st Jan 20173:36 pmRNSHardman Research: Further de-risking of iclaprim
31st Jan 20177:00 amRNSClinical trial finishes patient treatment phase
27th Jan 20176:13 pmRNSHolding(s) in Company
18th Jan 20177:05 amRNSDirector/PDMR Shareholding
18th Jan 20177:00 amRNSAppointment of Chief Financial Officer
9th Jan 20175:28 pmRNSIssue of Equity
3rd Jan 201712:31 pmRNSHolding(s) in Company
30th Dec 20163:09 pmRNSHolding(s) in Company
30th Dec 20162:38 pmRNSHolding(s) in Company
21st Dec 20165:50 pmRNSConversion of CPNs, PDMR Dealing & TVR
21st Dec 20164:17 pmRNSIssue of Equity & Total Voting Rights
21st Dec 20163:05 pmRNSResult of GM
19th Dec 20165:58 pmRNSHolding(s) in Company
8th Dec 20167:45 amRNSHolding(s) in Company
5th Dec 20167:00 amRNSPublication of circular and notice of GM
1st Dec 20165:27 pmRNSIssue of Equity
25th Nov 201611:32 amRNSHolding(s) in Company
24th Nov 20161:36 pmRNSHolding(s) in Company
23rd Nov 20165:12 pmRNSHolding(s) in Company
23rd Nov 20164:56 pmRNSClosing of public offer
18th Nov 201612:51 pmRNSConfirms successful European placing
18th Nov 20167:16 amRNSUS Pricing and European Placing to raise US$25m
4th Nov 20161:34 pmRNSHolding(s) in Company
4th Nov 20161:20 pmRNSHolding(s) in Company
31st Oct 20167:00 amRNSUpdate on US Public Offering
31st Oct 20167:00 amRNSData Confirming Standard Clinical Trial Dosage
31st Oct 20167:00 amRNSNew Data on Iclaprim
16th Sep 20164:40 pmRNSSecond Price Monitoring Extn
16th Sep 20164:35 pmRNSPrice Monitoring Extension
15th Sep 20167:00 amRNSPosters presented at IDWeek New Orleans

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.